UA91057C2 - Олигонуклеотид или его функциональный гомолог, композиция, содержащая его, и способ лечения в-клеточной опухоли - Google Patents

Олигонуклеотид или его функциональный гомолог, композиция, содержащая его, и способ лечения в-клеточной опухоли

Info

Publication number: UA91057C2
Authority: UA; Ukraine
Prior art keywords: oligonucleotide; composition; treating; same; functional homologue
Prior art date: 2005-05-17

Application number

UAA200714103A

Other languages

English (en)

Ukrainian (uk)

Inventor

Ли-ин Ван

Му-шен Бао

Юн-ли Юй

Original Assignee

Чанчунь Хуапу Байотекнолоджи Ко., Лтд.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-05-17

Filing date

2006-02-13

Publication date

2010-06-25

2006-02-13 Application filed by Чанчунь Хуапу Байотекнолоджи Ко., Лтд. filed Critical Чанчунь Хуапу Байотекнолоджи Ко., Лтд.

2010-06-25 Publication of UA91057C2 publication Critical patent/UA91057C2/ru

Links

108091034117 Oligonucleotide Proteins 0.000 title abstract 4
208000012526 B-cell neoplasm Diseases 0.000 title abstract 2
210000003719 b-lymphocyte Anatomy 0.000 abstract 3
210000005170 neoplastic cell Anatomy 0.000 abstract 3
101150013553 CD40 gene Proteins 0.000 abstract 1
102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 abstract 1
230000006907 apoptotic process Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/313—Phosphorodithioates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Biochemistry (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Immunology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Biophysics (AREA)
Microbiology (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Epidemiology (AREA)
Hematology (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Saccharide Compounds (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

UAA200714103A 2005-05-17 2006-02-13 Олигонуклеотид или его функциональный гомолог, композиция, содержащая его, и способ лечения в-клеточной опухоли UA91057C2 (ru)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CN2005100695764A CN1865275B (zh)	2005-05-17	2005-05-17	对人b细胞肿瘤有治疗作用的人工合成的单链脱氧核苷酸

Publications (1)

Publication Number	Publication Date
UA91057C2 true UA91057C2 (ru)	2010-06-25

Family

ID=37424439

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
UAA200714103A UA91057C2 (ru)	2005-05-17	2006-02-13	Олигонуклеотид или его функциональный гомолог, композиция, содержащая его, и способ лечения в-клеточной опухоли
UAA200714106A UA94231C2 (ru)	2005-05-17	2006-02-13	Олигонуклеотиды или их функциональные гомологи, композиция, которая содержит их, и способ лечения в-клеточной опухоли

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
UAA200714106A UA94231C2 (ru)	2005-05-17	2006-02-13	Олигонуклеотиды или их функциональные гомологи, композиция, которая содержит их, и способ лечения в-клеточной опухоли

Country Status (21)

Country	Link
US (3)	US20090202567A1 (ru)
EP (2)	EP1883411B1 (ru)
JP (2)	JP4837033B2 (ru)
KR (2)	KR101294131B1 (ru)
CN (1)	CN1865275B (ru)
AU (2)	AU2006246898B2 (ru)
BR (2)	BRPI0609885A2 (ru)
CA (2)	CA2609067A1 (ru)
CY (1)	CY1114844T1 (ru)
DK (2)	DK1883647T3 (ru)
ES (2)	ES2433129T3 (ru)
IL (2)	IL187249A (ru)
MX (2)	MX2007014145A (ru)
NZ (1)	NZ563582A (ru)
PL (2)	PL1883647T3 (ru)
PT (2)	PT1883647E (ru)
RU (2)	RU2413519C2 (ru)
SI (2)	SI1883411T1 (ru)
UA (2)	UA91057C2 (ru)
WO (2)	WO2006122463A1 (ru)
ZA (2)	ZA200710312B (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2728276A1 (en) *	2008-06-18	2009-12-23	Index Pharmaceuticals Ab	Combination therapies against cancer
CN101643496B (zh) *	2008-08-07	2015-09-09	长春华普生物技术有限公司	一种具有免疫抑制功能的寡核苷酸
US20110280934A1 (en) *	2008-11-04	2011-11-17	Asa Karlsson	Increased Expression of Specific Antigens
WO2012084991A1 (en) *	2010-12-21	2012-06-28	Index Pharmaceuticals Ab	Biologically active oligonucleotides capable of modulating the immune system ii
US9157919B2 (en) *	2010-12-21	2015-10-13	Index Pharmaceuticals Ab	Method for identifying biologically active oligonucleotides capable of modulating the immune system
CN106893724B (zh) *	2015-12-17	2023-05-02	苏州派动生物技术有限公司	具有抗原增效作用和肿瘤治疗作用的寡核苷酸
WO2021249011A1 (en)	2020-06-10	2021-12-16	Sichuan Clover Biopharmaceuticals, Inc.	Hiv vaccine compositions, methods, and uses thereof
WO2021249116A1 (en)	2020-06-10	2021-12-16	Sichuan Clover Biopharmaceuticals, Inc.	Coronavirus vaccine compositions, methods, and uses thereof
AU2024280139A1 (en)	2023-05-30	2026-01-22	Sichuan Clover Biopharmaceuticals, Inc.	Coronavirus vaccine composition, method therefor and use thereof
CN121464149A (zh)	2023-06-07	2026-02-03	四川三叶草生物制药有限公司	Rsv疫苗组合物、方法及其用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5736137A (en) *	1992-11-13	1998-04-07	Idec Pharmaceuticals Corporation	Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
DE19651443A1 (de) *	1996-12-11	1998-06-18	Hoechst Ag	Selbstverstärkende, pharmakologisch kontrollierbare Expressionssysteme
ATE297219T1 (de) *	1997-02-12	2005-06-15	Chugai Pharmaceutical Co Ltd	Antikörper als arzneimittel gegen lymphocytische tumore (ausschliesslich myelome)
NZ517929A (en)	1999-09-25	2004-02-27	Univ Iowa Res Found	Immunostimulatory nucleic acids
WO2001074388A1 (en) *	2000-03-31	2001-10-11	Idec Pharmaceuticals Corporation	Combined use of anti-cytokine antibodies or antagonists and anti-cd20 for the treatment of b cell lymphoma
EP1296714B1 (en)	2000-06-22	2009-08-26	University Of Iowa Research Foundation	Combination of CpG and antibodies directed against CD19,CD20, CD22 or CD40 for the treatment or prevention of cancer.
US20040009156A1 (en) *	2001-10-12	2004-01-15	Christoph Reinhard	Antisense therapy using oligonucleotides that target human kinesin genes for treatment of cancer
EP1465634B1 (en)	2001-12-12	2014-10-22	The Government of the United States of America, as represented by the Secretary Department of Health and Human Services	Methods for using adenosine receptor inhibitors to enhance immune response and inflammation
US7576066B2 (en) *	2002-07-03	2009-08-18	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
DE10258677A1 (de) *	2002-12-13	2004-06-24	Elez, Vera, Dr.	Kombinations-antisense-Oligonukleotid-Krebstherapie
CN100439386C (zh) *	2003-03-05	2008-12-03	长春华普生物技术有限公司	增强蛋白类疫苗免疫效果的含CpG单链脱氧寡核苷酸
CN100486987C (zh) *	2003-03-05	2009-05-13	长春华普生物技术有限公司	抗病毒和抗肿瘤的含CpG单链脱氧寡核苷酸
DE10333509B4 (de) *	2003-07-18	2007-05-03	Technische Universität Dresden	Gegen VEGF gerichtete Erkennungsmoleküle und die Verwendung dieser
US7491706B2 (en)	2003-07-25	2009-02-17	Changchun Huapu Biotechnology Co., Ltd.	Artificial cpg single-stranded oligodeoxynucleotide and antiviral use thereof
JP4513879B2 (ja)	2008-03-05	2010-07-28	ソニー株式会社	像ぶれ補正装置、レンズ鏡筒装置及びカメラ装置

2005
- 2005-05-17 CN CN2005100695764A patent/CN1865275B/zh not_active Expired - Lifetime
2006
- 2006-02-13 CA CA002609067A patent/CA2609067A1/en not_active Abandoned
- 2006-02-13 JP JP2008511531A patent/JP4837033B2/ja not_active Expired - Fee Related
- 2006-02-13 US US11/914,744 patent/US20090202567A1/en not_active Abandoned
- 2006-02-13 ZA ZA200710312A patent/ZA200710312B/xx unknown
- 2006-02-13 PL PL06705636T patent/PL1883647T3/pl unknown
- 2006-02-13 AU AU2006246898A patent/AU2006246898B2/en not_active Ceased
- 2006-02-13 ES ES06705637T patent/ES2433129T3/es not_active Expired - Lifetime
- 2006-02-13 SI SI200631687T patent/SI1883411T1/sl unknown
- 2006-02-13 WO PCT/CN2006/000215 patent/WO2006122463A1/en not_active Ceased
- 2006-02-13 PL PL06705637T patent/PL1883411T3/pl unknown
- 2006-02-13 KR KR1020077028308A patent/KR101294131B1/ko not_active Expired - Fee Related
- 2006-02-13 MX MX2007014145A patent/MX2007014145A/es active IP Right Grant
- 2006-02-13 NZ NZ563582A patent/NZ563582A/en not_active IP Right Cessation
- 2006-02-13 CA CA2609062A patent/CA2609062C/en not_active Expired - Fee Related
- 2006-02-13 UA UAA200714103A patent/UA91057C2/ru unknown
- 2006-02-13 DK DK06705636.6T patent/DK1883647T3/da active
- 2006-02-13 EP EP06705637.4A patent/EP1883411B1/en not_active Expired - Lifetime
- 2006-02-13 AU AU2006246897A patent/AU2006246897B2/en not_active Ceased
- 2006-02-13 RU RU2007146705/14A patent/RU2413519C2/ru not_active IP Right Cessation
- 2006-02-13 MX MX2007014146A patent/MX2007014146A/es active IP Right Grant
- 2006-02-13 US US11/914,745 patent/US8133874B2/en active Active
- 2006-02-13 RU RU2007146706/10A patent/RU2409672C2/ru not_active IP Right Cessation
- 2006-02-13 KR KR1020077028065A patent/KR101346716B1/ko not_active Expired - Fee Related
- 2006-02-13 EP EP06705636.6A patent/EP1883647B1/en not_active Expired - Lifetime
- 2006-02-13 SI SI200631728T patent/SI1883647T1/sl unknown
- 2006-02-13 BR BRPI0609885-1A patent/BRPI0609885A2/pt not_active IP Right Cessation
- 2006-02-13 UA UAA200714106A patent/UA94231C2/ru unknown
- 2006-02-13 JP JP2008511532A patent/JP4837034B2/ja not_active Expired - Fee Related
- 2006-02-13 ES ES06705636.6T patent/ES2442462T3/es not_active Expired - Lifetime
- 2006-02-13 PT PT67056366T patent/PT1883647E/pt unknown
- 2006-02-13 ZA ZA200710311A patent/ZA200710311B/xx unknown
- 2006-02-13 PT PT67056374T patent/PT1883411E/pt unknown
- 2006-02-13 BR BRPI0609882-7A patent/BRPI0609882A2/pt not_active IP Right Cessation
- 2006-02-13 DK DK06705637.4T patent/DK1883411T3/da active
- 2006-02-13 WO PCT/CN2006/000216 patent/WO2006122464A1/en not_active Ceased
2007
- 2007-11-08 IL IL187249A patent/IL187249A/en not_active IP Right Cessation
- 2007-11-08 IL IL187281A patent/IL187281A/en not_active IP Right Cessation
2011
- 2011-12-02 US US13/310,595 patent/US8450292B2/en not_active Expired - Fee Related
2014
- 2014-01-13 CY CY20141100024T patent/CY1114844T1/el unknown

Also Published As

Publication number	Publication date
MX2007014145A (es)	2008-03-07
PT1883647E (pt)	2014-01-20
US8450292B2 (en)	2013-05-28
CA2609062C (en)	2013-11-19
ZA200710311B (en)	2009-08-26
EP1883411B1 (en)	2013-08-14
RU2409672C2 (ru)	2011-01-20
JP2008539768A (ja)	2008-11-20
MX2007014146A (es)	2008-03-07
HK1113318A1 (en)	2008-10-03
SI1883411T1 (sl)	2014-01-31
KR20080007655A (ko)	2008-01-22
WO2006122463A1 (en)	2006-11-23
CA2609067A1 (en)	2006-11-23
RU2007146705A (ru)	2009-06-27
PL1883647T3 (pl)	2014-03-31
KR101294131B1 (ko)	2013-08-07
IL187281A0 (en)	2011-08-01
CY1114844T1 (el)	2016-12-14
KR20080011426A (ko)	2008-02-04
US8133874B2 (en)	2012-03-13
BRPI0609885A2 (pt)	2010-05-04
UA94231C2 (ru)	2011-04-26
ES2433129T3 (es)	2013-12-09
PT1883411E (pt)	2013-11-11
BRPI0609882A2 (pt)	2010-05-04
RU2007146706A (ru)	2009-06-27
SI1883647T1 (sl)	2014-02-28
IL187249A0 (en)	2008-02-09
CA2609062A1 (en)	2006-11-23
ZA200710312B (en)	2009-08-26
US20120142761A1 (en)	2012-06-07
JP2008539767A (ja)	2008-11-20
DK1883647T3 (da)	2014-01-27
AU2006246897A1 (en)	2006-11-23
EP1883647A4 (en)	2010-10-06
ES2442462T3 (es)	2014-02-11
JP4837033B2 (ja)	2011-12-14
DK1883411T3 (da)	2013-11-18
EP1883647B1 (en)	2013-10-23
EP1883411A4 (en)	2010-10-06
PL1883411T3 (pl)	2014-01-31
RU2413519C2 (ru)	2011-03-10
US20090162279A1 (en)	2009-06-25
US20090202567A1 (en)	2009-08-13
AU2006246898A1 (en)	2006-11-23
CN1865275B (zh)	2011-06-15
HK1112745A1 (en)	2008-09-12
AU2006246897B2 (en)	2012-04-12
WO2006122464A1 (en)	2006-11-23
EP1883647A1 (en)	2008-02-06
IL187281A (en)	2012-04-30
KR101346716B1 (ko)	2014-01-02
IL187249A (en)	2012-03-29
EP1883411A1 (en)	2008-02-06
NZ563582A (en)	2010-04-30
CN1865275A (zh)	2006-11-22
AU2006246898B2 (en)	2011-08-18
JP4837034B2 (ja)	2011-12-14

Publication	Publication Date	Title
NZ591416A (en)	2012-11-30	Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
GB0400584D0 (en)	2004-02-11	Nucleic acid chacterisation
GB2448448A (en)	2008-10-15	methods and system for conducting research operations
MX2010002974A (es)	2010-07-29	Formas solidas de n-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4- dihidro-4-oxoquinolin-3-carboxamida.
GB2465911A (en)	2010-06-09	Systems, methods, and processes utilized for treating subsurface formations
IL164228A0 (en)	2005-12-18	Antisense iap nucleobase oligomers and uses thereof
GB2462020A (en)	2010-01-27	Systems, methods, and processes for use in treating subsurface formations
NZ584827A (en)	2012-10-26	Antisense modulation of fibroblast growth factor receptor 4 expression
SG166091A1 (en)	2010-11-29	Method for producing isocyanates
MX2008001652A (es)	2008-04-07	Copolimeros de poliamonio-polisiloxano.
CY1114844T1 (el)	2016-12-14	Ολιγο-νουκλεοτιδιο (oligonucleotide) και συνθεσεις που το περιλαμβανουν για την θεραπεια νεοπλασματος β κυτταρων
GB0502482D0 (en)	2005-03-16	Novel compounds
TW200720232A (en)	2007-06-01	Crystalline solid forms of tigecycline and methods of preparing same
AU2003292202A1 (en)	2004-07-22	Hydrophilized blocked polyisocyanates
MY149864A (en)	2013-10-31	Flavouring-containing pharmaceutical formulations with improved pharmaceutical properties
BRPI0308119A2 (pt)	2016-06-28	microorganismo como portadores de seqüências de nucleotídeos codificando para antígenos de células para o tratamento de tumores.
UA83203C2 (ru)	2008-06-25	Тиазол-(би)циклоалкилкарбоксанилиды, средство на их основе и применение для борьбы с нежелательными микроорганизмами
TW200630348A (en)	2006-09-01	Tadalafil crystal forms and processes for preparing them
MXPA05012363A (es)	2006-02-02	Poliisocianatos bloqueados estables en la solidificacion.
MY136360A (en)	2008-09-30	Cyclohexane derivatives and methods for their preparation
TW200716132A (en)	2007-05-01	Novel chemical compounds
WO2009109102A8 (en)	2009-11-26	Recombinant microorganism and method for producing l-lysine
MX2008004899A (es)	2008-09-04	Compuestos y métodos para partículas de condensado de ácido ribonucleico de péptido para terapéuticos de arn.
PL1948689T3 (pl)	2012-09-28	Mutanty czynników wzrostu o wysokiej aktywności
UA91733C2 (ru)	2010-08-25	Способ получения кристаллической формы орлистата